FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309679231> ?p ?o ?g. }

• W4309679231 abstract "Summary BACKGROUND VLPCOV-01 is a lipid nanoparticle-encapsulated self-amplifying RNA (saRNA) vaccine that expresses a membrane-anchored receptor-binding domain (RBD) derived from the SARS-CoV-2 spike protein. METHODS A phase 1 study of VLPCOV-01 was conducted at Medical Corporation Heishinkai OPHAC Hospital, Japan. Participants aged 18 to 55 or ≥65 years who had completed two doses of the BNT162b2 mRNA vaccine 6 to 12 months previously were randomised to receive one intramuscular vaccination of 0·3, 1·0, or 3·0 μg VLPCOV-01, 30 μg BNT162b2, or placebo between February 16, 2022, and March 17, 2022. Solicited adverse events were collected up to 6 days post-administration. Interim immunogenicity analyses included SARS-CoV-2 IgG and neutralising antibody titres. Follow-up for safety and immunogenicity evaluation is ongoing. (The trial is registered: jRCT2051210164). FINDINGS 92 healthy adults were enrolled, with 60 participants receiving VLPCOV-01. No serious adverse events were reported up to 26 weeks, and no prespecified trial-halting events were met. VLPCOV-01 induced robust IgG titres against SARS-CoV-2 RBD protein that were maintained up to 26 weeks in non-elderly participants, with geometric means ranging from 5037 (95% CI 1272–19,940) at 0·3 μg to 12,873 (95% CI 937–17,686) at 3 μg, in comparison to 3166 (95% CI 1619–6191) with 30 μg BNT162b2. Among elderly participants, IgG titres at 26 weeks post-vaccination with 3 μg VLPCOV-01 were 9865 (95% CI 4396–22138) compared to 4183 (95% CI 1436–12180) following vaccination with 30 μg BNT162b2. Pseudovirus neutralising antibody responses were observed against multiple SARS-CoV-2 variants and strongly correlated with anti-SARS-CoV-2 IgG ( r =0·950, p<0·001). INTERPRETATION VLPCOV-01 is immunogenic following low dose administration, with anti-SARS-CoV-2 immune responses comparable to BNT162b2. These findings support further development of VLPCOV-01 as a COVID-19 booster vaccine and the potential for saRNA vectors as a vaccine platform. FUNDING Supported by AMED, Grant No. JP21nf0101627." @default.
• W4309679231 created "2022-11-29" @default.
• W4309679231 creator A5002547697 @default.
• W4309679231 creator A5004628851 @default.
• W4309679231 creator A5010423768 @default.
• W4309679231 creator A5010836657 @default.
• W4309679231 creator A5016494193 @default.
• W4309679231 creator A5027094933 @default.
• W4309679231 creator A5028745610 @default.
• W4309679231 creator A5035861574 @default.
• W4309679231 creator A5036393679 @default.
• W4309679231 creator A5036651667 @default.
• W4309679231 creator A5039077926 @default.
• W4309679231 creator A5041424756 @default.
• W4309679231 creator A5050151329 @default.
• W4309679231 creator A5053520990 @default.
• W4309679231 creator A5059968573 @default.
• W4309679231 creator A5068980430 @default.
• W4309679231 creator A5075631124 @default.
• W4309679231 creator A5076687585 @default.
• W4309679231 creator A5080759680 @default.
• W4309679231 creator A5082218499 @default.
• W4309679231 creator A5088055510 @default.
• W4309679231 date "2022-11-22" @default.
• W4309679231 modified "2023-10-16" @default.
• W4309679231 title "Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study" @default.
• W4309679231 cites W1963905773 @default.
• W4309679231 cites W2042249918 @default.
• W4309679231 cites W2116546550 @default.
• W4309679231 cites W2775712816 @default.
• W4309679231 cites W3043722389 @default.
• W4309679231 cites W3081892744 @default.
• W4309679231 cites W3086125063 @default.
• W4309679231 cites W3090844627 @default.
• W4309679231 cites W3111255098 @default.
• W4309679231 cites W3119345685 @default.
• W4309679231 cites W3153508314 @default.
• W4309679231 cites W3163976770 @default.
• W4309679231 cites W3178010802 @default.
• W4309679231 cites W3189544042 @default.
• W4309679231 cites W3190606158 @default.
• W4309679231 cites W3200511289 @default.
• W4309679231 cites W3206370075 @default.
• W4309679231 cites W3211505703 @default.
• W4309679231 cites W4205483821 @default.
• W4309679231 cites W4211200665 @default.
• W4309679231 cites W4213102925 @default.
• W4309679231 cites W4220689791 @default.
• W4309679231 cites W4220886953 @default.
• W4309679231 cites W4220898781 @default.
• W4309679231 cites W4220904663 @default.
• W4309679231 cites W4226208081 @default.
• W4309679231 cites W4226310502 @default.
• W4309679231 cites W4283395367 @default.
• W4309679231 cites W4291119573 @default.
• W4309679231 cites W4293843074 @default.
• W4309679231 doi "https://doi.org/10.1101/2022.11.21.22281000" @default.
• W4309679231 hasPublicationYear "2022" @default.
• W4309679231 type Work @default.
• W4309679231 citedByCount "1" @default.
• W4309679231 countsByYear W43096792312023 @default.
• W4309679231 crossrefType "posted-content" @default.
• W4309679231 hasAuthorship W4309679231A5002547697 @default.
• W4309679231 hasAuthorship W4309679231A5004628851 @default.
• W4309679231 hasAuthorship W4309679231A5010423768 @default.
• W4309679231 hasAuthorship W4309679231A5010836657 @default.
• W4309679231 hasAuthorship W4309679231A5016494193 @default.
• W4309679231 hasAuthorship W4309679231A5027094933 @default.
• W4309679231 hasAuthorship W4309679231A5028745610 @default.
• W4309679231 hasAuthorship W4309679231A5035861574 @default.
• W4309679231 hasAuthorship W4309679231A5036393679 @default.
• W4309679231 hasAuthorship W4309679231A5036651667 @default.
• W4309679231 hasAuthorship W4309679231A5039077926 @default.
• W4309679231 hasAuthorship W4309679231A5041424756 @default.
• W4309679231 hasAuthorship W4309679231A5050151329 @default.
• W4309679231 hasAuthorship W4309679231A5053520990 @default.
• W4309679231 hasAuthorship W4309679231A5059968573 @default.
• W4309679231 hasAuthorship W4309679231A5068980430 @default.
• W4309679231 hasAuthorship W4309679231A5075631124 @default.
• W4309679231 hasAuthorship W4309679231A5076687585 @default.
• W4309679231 hasAuthorship W4309679231A5080759680 @default.
• W4309679231 hasAuthorship W4309679231A5082218499 @default.
• W4309679231 hasAuthorship W4309679231A5088055510 @default.
• W4309679231 hasBestOaLocation W43096792311 @default.
• W4309679231 hasConcept C126322002 @default.
• W4309679231 hasConcept C142724271 @default.
• W4309679231 hasConcept C159654299 @default.
• W4309679231 hasConcept C197934379 @default.
• W4309679231 hasConcept C203014093 @default.
• W4309679231 hasConcept C204787440 @default.
• W4309679231 hasConcept C22070199 @default.
• W4309679231 hasConcept C27081682 @default.
• W4309679231 hasConcept C2780868878 @default.
• W4309679231 hasConcept C71924100 @default.
• W4309679231 hasConceptScore W4309679231C126322002 @default.
• W4309679231 hasConceptScore W4309679231C142724271 @default.
• W4309679231 hasConceptScore W4309679231C159654299 @default.
• W4309679231 hasConceptScore W4309679231C197934379 @default.
• W4309679231 hasConceptScore W4309679231C203014093 @default.
• W4309679231 hasConceptScore W4309679231C204787440 @default.

• next